soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM SOUL Trial (NEJM 2025): Oral

When you take our free assessment quiz, you initiate a process where medical professionals develop a personalized plan, considering potential side effects and how to manage them, including when and how to adjust dosages to optimize your comfort and results

One in three patients achieved weight loss of more than 20% a level that can translate into meaningful improvements in daily functioning and quality of life for people living with obesity

However, you should consult a doctor to determine the underlying cause of the condition and get proper guidance on treatment options

Once reconstituted with bacteriostatic water, the peptide is in solution and far more vulnerablerefrigeration at 2-8C becomes mandatory

Serious nausea, vomiting and diarrhea can lead to dehydration and worsen kidney function